NewLink Genetics Corporation (NASDAQ: NLNK) 34.5% LOWER; announced today results of its Phase 3 clinical trial for algenpantucel-L for patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Special Reports

Mizuho Securities Cuts Price Target on NewLink Genetics (NLNK) Following Failed IMPRESS Trial May 10, 2016 1:22 PM Piper Jaffray Remains Bullish as Applied Optoelectronics (AAOI) Reports 1Q In-Line with Pre-Announcement May 10, 2016 9:36 AM Stifel Cuts Price Target on Gap, Inc. (GPS) Following Weak April Results May 10, 2016 9:27 AM Leerink Partners Raises Price Target on Diplomat Pharmacy (DPLO) to $36 Following 1Q Beat May 10, 2016 9:00 AM FBR Capital Remains Sidelined on Gap, Inc. (GPS) Following April Review May 10, 2016 8:41 AM Piper Jaffray Cuts Price Target on Fiesta Restauran (FRGI) as Margins Impact 1Q Miss May 10, 2016 7:44 AM Wedbush Cuts Price Target on Gap, Inc. (GPS) to $19 Following Weak April May 10, 2016 7:37 AM